ARV-471
AssetAlso PF-07850327, Vepdegestrant
Estrogen receptor PROTAC degrader for treating estrogen receptor-positive breast cancer.
- Stage
- Phase 1
- Modality
- Small molecule
- Target
- Proteostasis
- 1
- Indication
- 642
- Trials
- 1
- Developer
Indications
1Breast cancer
Phase 1, Completed, NCT05501769, clinicaltrials.gov, 7 Oct 2026
In the full profile
- Targets and what it contains3
- Owner and partners1
- Trials642
- Evidence for its targets3
- Competitors12
- Aging relevance1
- Signals2
Every asset’s record: target, stage, trials and the evidence behind it.